Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Spanish Breast Cancer Research Group"
Count: 52
Selected: 0
| NCT ID | Title |
|---|
| NCT05063786 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | ||
| NCT00545077 | Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women | ||
| NCT03390894 | Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies | ||
| NCT05744375 | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab | ||
| NCT00130533 | Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients | ||
| NCT04603820 | Registry Study of Pregnancy and Breast Cancer | ||
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer | ||
| NCT03800355 | Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk | ||
| NCT02819882 | A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) | ||
| NCT05252988 | Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | ||
| NCT04370522 | Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer | ||
| NCT04379908 | Healthy Lifestyles and Quality of Life in Women With Breast Cancer | ||
| NCT04293393 | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | ||
| NCT00128310 | Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients | ||
| NCT01875367 | Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer | ||
| NCT00258960 | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | ||
| NCT00121992 | Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment | ||
| NCT03025880 | Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC | ||
| NCT02027376 | Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients | ||
| NCT00432172 | Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | ||
| NCT00841828 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | ||
| NCT00129935 | EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer | ||
| NCT01565499 | Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer | ||
| NCT01306942 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | ||
| NCT00128297 | Pamidronate Administration in Breast Cancer Patients With Bone Metastases | ||
| NCT01377363 | Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis | ||
| NCT00543127 | Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | ||
| NCT01298193 | Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. | ||
| NCT00129389 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | ||
| NCT03847220 | Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis | ||
| NCT03210974 | Retrospective Observational Study About Evolution of Patients With Breast Cancer in Hospitals From GEICAM Group | ||
| NCT00129922 | Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer | ||
| NCT00129896 | Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | ||
| NCT00128856 | Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | ||
| NCT00128843 | Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | ||
| NCT00128778 | Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients | ||
| NCT03860740 | Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients | ||
| NCT03829306 | Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA) | ||
| NCT03205761 | Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | ||
| NCT02028507 | Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | ||
| NCT02690480 | Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | ||
| NCT01733628 | Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer | ||
| NCT00129376 | Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients | ||
| NCT00130494 | Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions | ||
| NCT00130507 | Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab | ||
| NCT00434941 | Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours | ||
| NCT01598285 | A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer | ||
| NCT05181462 | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. | ||
| NCT02413008 | A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting | ||
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) |
